[ad_1]
Health Minister Fahrettin Koca made a statement after the Scientific Committee.
“An optional 30 million dose agreement was signed with BioNTech”
Noting that more than 14 million doses of vaccine have been administered so far, Minister Koca said:
“The vaccine that we receive for use from abroad, more than a total of 18 million doses. In addition, today, corresponding to 10 million doses, the recharge will be carried out in Turkey, the vaccine has reached our hands. The total of 100 million doses if withdrawn at the end of May, we hope to reach Turkey. The deal is done this way. “
Stating that a new agreement has been made with BioNTech, Koca shared the following information:
“As you know, until recently we ran the process with the Sinovac vaccine. Now, the German BioNTech vaccine is also involved. Today 1.4 million doses of the BioNTech vaccine have been reached. At the beginning of April, it will reach 4.5 million doses Additional Olaraksa 30 Million doses have been made for the biontech option agreement where production capacity increases at the beginning of Turkish scientists, Turkey will benefit more from the vaccine.
.jpg)
We are closely following the development processes of the Russian-sourced Sputnik V vaccine, which is widely known to the public. The first negotiations for the acquisition of Sputnik have begun. This vaccine will be widely used after the testing process to ensure its suitability. “
“The domestic vaccine will begin Phase 3 at the end of April”
In reference to the national vaccination studies, Health Minister Koca announced that phase 3 studies will start in April:
“Our domestic vaccination studies, with this understanding, make significant progress towards the result. The inactivated vaccine developed by the Erciyes University is in Phase 2. The second dose of the vaccine for the last volunteer will be held on April 9, after the results have been achieved. At the end of April, the final stage, Phase 3, will be passed.
Another important advance is the following: Our country has begun Phase 1 studies of the VLP virus-like particles (that is, virus-like particles) vaccine. This type of vaccine is one of the most innovative vaccine candidates in the world.
There are other developments that need to be listed with respect to the domestic vaccine: in short, I can cite an inactivated vaccine that started phase 1 human studies and another inactivated vaccine that takes a few days to move to phase 1 studies as two examples. “
“Phase 1 studies of the intranasal Covid vaccine will begin very soon”
Stating that Turkish scientists have achieved a breakthrough and that the vaccine can be administered as a nasal spray, Minister Koca said:
“Besides these, the following development is very remarkable: Because there is a new technique in the vaccine. In this new technique, the aim is to apply the vaccine as an aerosol through the nose.
Phase 1 studies of this vaccine, called the intranasal Covid vaccine, will begin very soon. If this initiative by Turkish scientists works, this will be the first intranasal Covid vaccine in the world. 250 million doses of this vaccine, which has a very high production efficiency, can be produced annually in a single facility. “
Stating that the coronavirus will be under control when the vaccination is completed, Koca said: “More than 100 million doses of vaccine will be available by the end of May. More than 50 million people will be vaccinated and protection will begin in most of they.”
[ad_2]
